GLP-1 stands for glucagon-like peptide-1, a satiety hormone the body produces when we eat to help stimulate digestion and ...

Multiple factors are negatively impacting the compounded Semaglutide market. Insurance coverage for GLP-1s, like Wegovy, still varies widely from plan to plan. Demand for Semaglutide and other GLP-1s ...

With a U.S. Food and Drug Administration ban on copycat semaglutide drugs now in effect, Novo Nordisk is launching a series of initiatives to improve access to authentic versions of its ...

PLAINSBORO, N.J., May 22, 2025 /PRNewswire/ -- Today, as the US Food and Drug Administration (FDA) grace period for mass compounding of "semaglutide" expires, Novo Nordisk announced a series of ...

Novo Nordisk alleges the clinics unauthorized use of compounded drugs containing semaglutide means those medications have not been evaluated by the FDA — further suggesting the medication has ...

As the FDA’s ban on mass compounding of semaglutide takes effect, Novo Nordisk introduces discounted pricing and new patient resources to ensure safe access to Wegovy. Novo Nordisk has announced ...

The supply of GLP-1 drugs for weight loss and diabetes treatment was expected to tighten this week with a federal deadline to halt the sale and production of off-brand products that many patients ...

Thursday was the final cut-off for compounded semaglutide. The Outsourcing Facilities Association, a trade group representing compounding pharmacies, challenged the FDA’s decision in court ...

The company also said that insured patients can pay as little as $0 per month. "Mass compounding of 'semaglutide' is illegal, dangerous, and must stop now, which is why we are doubling down on our ...